Exelixis reported $342.78M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 112.52M 15.68M
Akebia Therapeutics AKBA:US $ 38.68M 21.44M
Amgen AMGN:US $ 4677M 451M
AstraZeneca AZN:LN 9.11B 169M
Bayer BAYN:GR 9.46B 2.03B
Biomarin Pharmaceutical BMRN:US $ 402.39M 72.33M
Bristol Myers Squibb BMY:US $ 9177M 452M
Eisai 4523:JP Y 140163M 18587M
Eli Lilly And LLY:US $ 5737.9M 211.8M
Esperion Therapeutics ESPR:US $ 11.71M 1.38M
Exelixis EXEL:US $ 342.78M 95.45M
Glaxosmithkline GSK:US $ 6135M 283M
IONIS PHARMACEUT IONS:US $ 137.75M 300.03M
MacroGenics MGNX:US 11.05M 2.15M
Merk MRK:US $ 10567M 873M
Moderna Inc MRNA:US 5.05B 1.21B
Nektar Therapeutics NKTR:US $ 18.85M 0.76M
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Novartis NOVN:VX 9.06B 463M
Pfizer PFE:US $ 15651M 1516M
Puma Biotechnology PBYI:US $ 34.89M 8.57M
Seattle Genetics SGEN:US $ 338.83M 4.33M
Takeda 4502:JP Y 564909M 54981M
Ultragenyx Pharmaceutical RARE:US $ 73.83M 6.04M
YTE INCY:US $ 696.02M 128.26M